Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27400778 | 0.80 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1CCR1CCR5CCR8 | |
| SCHEMBL22820306 | 0.78 | CCR1 (0.39) | HSP90AA1HSP90AB1CCR1CCR5CCR8 | |
| SCHEMBL17434548 | 0.77 | AGXT (0.64) | HSP90AA1HSP90AB1AGXT | |
| SCHEMBL9828008 | 0.76 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1CCR1CCR5CCR8 | |
| SCHEMBL14366752 | 0.76 | AGXT (0.40) | HSP90AA1HSP90AB1CCR1CCR5CCR8 | |
| SCHEMBL3396036 | 0.76 | CCR1 (0.38) | HSP90AA1HSP90AB1CCR1CCR5CCR8 | |
| SCHEMBL1758565 | 0.76 | AGXT (0.40) | HSP90AA1HSP90AB1CCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL189901 | 0.74 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1CCR1CCR5CCR8 | |
| SCHEMBL27321413 | 0.74 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1 | |
| SCHEMBL27562249 | 0.71 | CCR1 (0.34) | HSP90AA1HSP90AB1CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HSP90AA1 2576/4885HSP90AB1 2036/4885CCR1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.